Amneal Lanreotide Generic FDA Approval Launch
Analysis based on 10 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026
The approval gives Amneal a new revenue driver in a roughly $983 million U.S. market and pressures Ipsen's branded Somatuline franchise as generic competition enters. Investor reaction was modestly positive, with AMRX rising 2.35% on the announcement.
Amneal Pharmaceuticals received U.S. United States — Food and Drug Administration approval for its lanreotide injection, 120 mg/0.5 mL, a generic version of Somatuline Depot, and launched the product immediately. The approval carries Competitive Generic Therapy designation. Lanreotide is indicated for acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. Somatuline Depot, originally developed by Ipsen, had U.S. annual sales of $983 million for the 12 months ended July 2026 according to IQVIA. Amneal will produce the drug in-house with dedicated large-scale manufacturing capacity. AMRX shares closed up 2.35% at $18.71 on the news.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard